Multibillion-dollar cancer drug from Genentech loses 2nd FDA approval

Five years ago, the FDA had granted a conditional "accelerated approval" of the drug in certain bladder cancer patients. But the company said a new study failed to hit marks that would convert the drug to a full approval.